Athenahealth’s (ATHN) shares have gained more than 20% today, which means that their results weren’t just good, but completely reset Wall Street’s expectations.
Agence France-Presse/Getty ImagesWhich is exactly what Athenahealth did. The online billing and medical data company reported a profit of 57 cents a share, well above forecasts for 44 cents, thanks to better profit margins.
If that was all, Athenahealth’s shares would have gained a few percentage points. Instead its stock has surged 25% to $173.82 at 3:56 p.m. The reason: the “best is yet to come,” says Sterne Agee’s Greg Bolan. He explains:
In our view, [Athenahealth] possesses the strongest position to harvest opportunities arising from the invariable chaos created by ICD-10 [a revamp of the World Health Organization's disease codes. Ed.] in October. In a recent investor call with the AC Group…CEO Mark Anderson estimated that of the 1.1MM billable healthcare providers (active physicians and nurse practitioners) in the U.S., 20-25% will be transitioned to an outsourced billing service following the implementation of ICD-10 in October 2014. To put his point into perspective, we are modeling for 10,400 new physicians to go live on Collector in 2014. Mr. Anderson was quite vocal about the superiority of athenaCollector to ambulatory RCM services provided by eCW (private), Quality Systems (QSII), and CareCloud (private). We continue to believe Athena has the “mouse trap” technology for outsourced billing services to hospital-owned and independent practices.
5 Best Quality Stocks To Invest In 2015: Chalmers Ltd (CHR)
Chalmers Limited is an Australia-based company engaged in transport, logistic services, warehousing and container storage, repairs and sales. The Company operated in three segments: Transport, Containers and Property. Transport consists of road transport, predominantly import/export FCL containers and the interface with logistics/ warehousing/hubbing services. Containers represent the empty container park operations concerned with handling, storage, repairs, upgrades, pretrips and so on of empty containers on behalf of shipping and leasing company customers. Property represents the capital investment Chalmers has in freeholds located in Melbourne. The Company�� subsidiaries include Chalmers Industries Pty Ltd, Chalmers (Australia) Pty Ltd and Chalmers Industries (Brisbane) Pty Ltd. Advisors' Opinion:- [By Corinne Gretler]
Chr. Hansen A/S (CHR) slid 1.7 percent to 186 kroner after Credit Suisse Group AG cut the stock to neutral, the equivalent of hold, from outperform. The brokerage said that profit from its natural-color business remains under pressure. The world�� biggest maker of dairy enzymes cut its full-year sales forecast on July 3 because of lower prices for the red pigment carmine.
5 Best Quality Stocks To Invest In 2015: TFS Financial Corporation(TFSL)
TFS Financial Corporation operates as a holding company for Third Federal Savings and Loan Association of Cleveland. The company provides retail consumer banking, including mortgage lending, deposit gathering, and other financial services in Ohio and Florida. Its deposit accounts consist of savings accounts, negotiable order of withdrawal accounts, certificates of deposit accounts, individual retirement accounts, and other qualified plan accounts. The company also offers residential real estate mortgage loans, home equity loans, lines of credit, residential construction loans, and consumer loans. It operates 39 full-service branches and 8 loan production offices. TFS Financial Corporation, through its subsidiary, Third Capital, Inc. engages in net lease transactions of commercial buildings; maintains minority investments in private equity funds, and provide escrow and settlement services; and reinsures private mortgage insurance on residential mortgage loans. The company w as founded in 1938 and is headquartered in Cleveland, Ohio.
Advisors' Opinion:- [By Jim Royal]
The special situation
For those of you following my Special Situations portfolio, Investors Bancorp is in a spot similar to First Financial Northwest (NASDAQ: FFNW ) and TFS Financial (NASDAQ: TFSL ) , both of which are featured substantially in the portfolio. While Investors Bancorp is still only a partially demutualized thrift (like TFS Financial today), it will soon become a fully public institution, like First Financial.
Top 5 Information Technology Stocks To Watch Right Now: Vanda Pharmaceuticals Inc.(VNDA)
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is also developing Tasimelteon, an orphan medicinal product for the treatment of sleep and mood disorders, including non-24 hour sleep/wake disorder in blind individuals without light perception. It also intends to initiate a Phase IIb/III clinical trial of tasimelteon in patients with major depressive disorder; and conduct additional clinical trials to support the use of tasimelteon as a circadian regulator. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.
Advisors' Opinion:- [By Ben Levisohn]
It was the night before the ECB–and two before US payrolls–and all through the market nothing was stirring, not even…Alright. Some things were stirring, like the shares of Protective Life (PL), Travelers Companies (TRV), Under Armour (UA), Broadcom (BRCM) and Vanda Pharmaceuticals (VNDA).
- [By Paul Ausick]
Stocks on the Move: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is up 95.8% at $13.29 on FDA recommendation for approval of its sleep drug for the blind. Sarepta Therapeutics Inc. (NASDAQ: SRPT) is down 64.3% at $13.05 following an FDA rejection of the company�� bid to fast-track muscular dystrophy drug. U.S. Airways Group Inc. (NYSE: LCC) is up 1.1% at $23.53 after reaching an agreement with the Department of Justice that will let the company go ahead with its American Airlines merger.
- [By Roberto Pedone]
Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.
If you take a look at the chart for Vanda Pharmaceuticals, you'll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.
Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.
Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Nathalie Tadena]
Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).
5 Best Quality Stocks To Invest In 2015: Vivendi SA (VIVHY.PK)
Vivendi SA (Vivendi), incorporated on December 18, 1987, is a communications and entertainment company. As of December 31, 2009, the Company had six business segments: Activision Blizzard, Universal Music Group, SFR, Maroc Telecom Group, GVT (Holding) S.A. (GVT) and Canal+ Group. Activision Blizzard develops, publishes and distributes interactive entertainment software, online or on other media (such as console and personal computer (PC)). Universal Music Group is engaged in the sale of recorded music (physical and digital media), exploitation of music publishing rights, as well as artist services and merchandising. SFR is engaged in the phone services (mobile, broadband Internet and fixed) in France. Maroc Telecom Group is a telecommunication operator (mobile, fixed and Internet) in Africa, principally in Morocco, as well as in Mauritania, Burkina Faso, Gabon and Mali. GVT is a Brazilian fixed and broadband operator. Canal+ Group is engaged in publishing and distribution of pay-television mainly in France, in both analog and digital (terrestrially, via satellite or ADSL), as well as film production in Europe. In July 2013, Vivendi SA and Universal Music Group announced the completion of the sale of Parlophone Label Group to Warner Music Group Corp.
On November 13, 2009, Vivendi acquired an aggregate of 29.9% of GVT�� outstanding voting shares from Swarth Investments LLC, Swarth Investments Holdings LLC and Global Village Telecom (Holland) BV. In addition, Vivendi acquired from third parties an additional 8% interest in GVT's outstanding shares. On December 28, 2009, Canal+ Group, Vivendi�� subsidiary, acquired TF1�� 9.9% interest in the capital of Canal+ France. On July 31, 2009, Maroc Telecom acquired 51% controlling interest in Sotelma. On August 27, 2009, CID, a company 40% owned by SFR and 60% by other financial investors, acquired the 62% interest in 5 sur 5.
Advisors' Opinion:- [By Mike Arnold]
I normally don't look at charts much, but comparing Orange to its competitors in the French telecommunications market is quite fascinating. As one can see, incumbents Bouygues (BOUYF.PK) and Vivendi (VIVHY.PK) (owner of SFR) saw similar price declines. The market, on the other hand, rapidly bid up the price of new entrant Iliad SA (ILIAF.PK), as a result of forecasts for Iliad to capture significant mobile market share (which it did, around 10%). The wide divergence in price relative to changes in underlying value favor going long the incumbents, including Orange. Because this time it's different.
- [By Eric Rodawig]
Activision Blizzard (ATVI) is the world's largest and most successful video game developer, and is majority owned (61%) by French telecom and media conglomerate Vivendi (VIVHY.PK). Vivendi has been undergoing a massive strategic review with the intent to reduce debt and unlock the value of its assets that has fueled speculation surrounding ATVI. In conjunction with this, ATVI CFO Dennis Durkin announced on the 4Q12 earnings call
5 Best Quality Stocks To Invest In 2015: Cytokinetics Incorporated(CYTK)
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. It primarily offers omecamtiv mecarbil, a cardiac muscle myosin activator, which is in Phase I/IIa clinical trials for the treatment of heart failure; CK-2017357, which is a Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis; and CK-2066260, a fast skeletal muscle sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting. The company?s cancer treatment products under development stage comprise ispinesib, SB-743921, and GSK-923295. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. The company was founded in 1997 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biopharmaceutical company Cytokinetics (NASDAQ: CYTK ) has received a distressing two-star ranking.
- [By Rich Duprey]
Biopharmaceutical Cytokinetics (NASDAQ: CYTK ) announced yesterday that it will be effecting a 1-for-6 reverse stock split to reduce the number of outstanding shares from�approximately 163.6 million to approximately 27.3 million shares.
- [By Sean Williams]
What: Shares of Cytokinetics (NASDAQ: CYTK ) , a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases, tanked as much as 38% after reporting mid-stage top-line data from acute heart failure drug, omecamtiv mecarbil.
- [By Rick Munarriz]
Tuesday
Cytokinetics (NASDAQ: CYTK ) checks in on Tuesday. The biotech company's lead candidate is a cardiac muscle contractility program that Cytokinetics is trying to get approved for the potential treatment of heart failure. Investors see red ink here, but analysts do see the quarterly deficit narrowing this time around.
No comments:
Post a Comment